We have characterized the mechanism whereby a G protein-coupled receptor, the alpha 1adrenergic receptor, promotes cellular AA release via the activation of phospholipase A2 (PLA2) in Madin-Darby canine kidney (MDCK-D1) cells. Stimulation of cells with the receptor agonist epinephrine or with the protein kinase C (PKC) activator PMA increased AA release in intact cells and the activity of PLA2 in subsequently prepared cell lysates. The effects of epinephrine were mediated by alpha 1-adrenergic receptors since they were blocked by the alpha 1-adrenergic antagonist prazosin. Epinephrine-and PMA-promoted AA release and activation of the PLA2 were inhibited by AACOCF3, an inhibitor of the 85-kD cPLA2. The 85-kD cPLA2 could be immunoprecipitated from the cell lysate using a specific anti-cPLA2 serum. Enhanced cPLA2 activity in cells treated with epinephrine or PMA could be recovered in such immunoprecipitates, thus directly demonstrating that alpha 1-adrenergic receptors activate the 85-kD cPLA2. Activation of cPLA2 in cell lysates by PMA or epinephrine could be reversed by treatment of lysates with exogenous phosphatase. In addition, both PMA and epinephrine induced a molecular weight shift, consistent with phosphorylation, as well as an increase in activity of mitogen-activated protein (MAP) kinase. The time course of epinephrine-promoted activation of MAP kinase preceded that of the accumulation of released AA and correlated with the time course of cPLA2 activation. Down-regulation of […] Research Article Find the latest version: http://jci.me/118546-pdf 1302 M. Xing and P.A. Insel J. Clin. Invest.
Introduction
AA and its eicosanoid metabolites (e.g., prostaglandins and leukotrienes) play critical roles in the initiation or modulation of a broad spectrum of physiological responses and certain abnormal (e.g., inflammatory) processes in mammalian cells (1, 2) . This fatty acid is not freely stored in cells but is esterified to cellular phospholipids, mainly at the sn -2 position. Its release can be catalyzed by phospholipase A 2 (PLA 2 ) 1 and is believed to be the limiting step in the biosynthesis of eicosanoids in response to stimulation by receptors such as G protein-coupled receptors. Three groups of mammalian PLA 2 s have been characterized, namely, the 14-kD Ca 2 ϩ -dependent secreted PLA 2 s, the 85-kD Ca 2 ϩ -dependent and sn -2 arachidonyl-specific cytosolic PLA 2 (cPLA 2 ), and the Ca 2 ϩ -independent PLA 2 s (3, 4) . Overexpression of Chinese hamster ovary cells with recombinant cPLA 2 enhanced AA release stimulated by ATP or thrombin receptors (5) . However, little definitive evidence is available for the coupling of the native cPLA 2 to receptors, particularly G protein-coupled receptors, although it has been proposed, largely based on indirect evidence, that the cPLA 2 is responsible for G protein-coupled receptor-mediated AA release (3, 6) . Furthermore, more recent studies have suggested that the 14-kD secreted group II PLA 2 (7, 8) , the calcium-independent PLA 2 (9) , and a 29-kD cytosolic PLA 2 (10) could each be responsible for AA release mediated by receptors.
Numerous studies have implicated the involvement of protein kinase C (PKC) in the regulation of receptor-mediated AA release in a variety of cells (3, 6, 11) . Nevertheless, in vitro studies have failed to consistently show direct phosphorylation-dependent activation of cPLA 2 by PKC (12) (13) (14) . Because mitogen-activated protein (MAP) kinase, which has been shown in vitro to phosphorylate and activate the recombinant cPLA 2 (12, 13) , can be stimulated in cells through both PKCdependent and independent pathways, it has been proposed that the PKC-dependent activation of cPLA 2 is via the activation of MAP kinase (12) . However, incomplete information is available regarding the relationship of the activation of PKC and MAP kinase with that of the endogenous cPLA 2 by G protein-coupled receptors in native cells, although activation of each of these enzymes has been separately studied in many reports. In fact, MAP kinase stimulation and Ca 2 ϩ mobilization promoted by G protein-coupled P 2U receptors fail to stimulate cPLA 2 -mediated AA release in undifferentiated HL60 cells (15) . Furthermore, in Chinese hamster ovary cells a G i2 ␣ mutant inhibits G protein-coupled P 2 -purinergic receptor-or thrombin receptor-promoted AA release by cPLA 2 while not altering Ca 2 ϩ mobilization, MAP kinase activation, and phosphorylation of cPLA 2 (16) . Thus, the role of MAP kinase, and its relationship with PKC, in the regulation of the endogenous cPLA 2 by G protein-coupled receptors need to be further defined in native cells. Alpha 1 -adrenergic receptors are an important class of the G protein-coupled receptors. They play fundamental roles in the regulation of a wide variety of cardiovascular, renal, and metabolic functions (17) . These receptors are also coupled to release of AA and eicosanoids in many cells. Although some evidence, such as assessment of lysophospholipid formation, has suggested that PLA 2 is involved (18) , no data has directly defined which type of PLA 2 , if any, mediates ␣ 1 -adrenergic receptor-promoted AA release in cells. Moreover, the specific mechanism(s) regulating this receptor-promoted activation of PLA 2 , especially in terms of involvement of protein kinases, has not been defined. In the present study with Madin-Darby canine kidney (MDCK)-D1 cells, we investigated the molecular mechanism for the regulation of AA release by ␣ 1 -adrenergic receptors. We demonstrate that ␣ 1 -adrenergic receptors stimulate AA release in MDCK-D1 cells by phosphorylationdependent activation of the 85-kD cPLA 2 , which involves activation of PKC and MAP kinase.
Methods
Materials. Leupeptin, pepstatin A, A23187, PMA, AACOCF 3 , and PMSF were purchased from Calbiochem Corp. (La Jolla, CA). DTT was obtained from Boehringer Mannheim Biochemicals (Indianapolis, IN). [5,6,8,9,11,12,14,15- (19) . Standard 85-kD cPLA 2 protein and its specific antiserum were from Dr. Lih-ling Lin (Genetics Institute, Cambridge, MA) (5) . PD098059 was from Dr. Alan R. Saltiel (Parke-Davis, Ann Arbor, MI) (20) .
Cell culture. MDCK-D1 cells were cultured as previously described (21) . Subconfluent cells were subcultured every 3-4 d by trypsinization using trypsin/EDTA. Cells at 60-80% confluence usually achieved 3 d after the subculture were normally used for experiments.
[ 3 H]AA release in intact cells. After labeling with 0.5 Ci [ 3 H]AA/ ml per well for 20 h in a 24-well plate, cells were washed four times with serum-and NaHCO 3 -free DME supplemented with 5 mg/ml BSA and 20 mM Hepes, pH 7.4, and incubated in the same medium at 37 Њ C for 15 min to equilibrate the temperature. Stimulation of cells was then started by replacing the medium with 1 ml of 37 Њ C medium containing the specified agonists. After a 10-min incubation in a 37 Њ C water bath with constant agitation, the stimulation was stopped by aspirating the incubation medium and transferring it to ice-cold tubes containing 100 l of 55 mM EGTA and EDTA (final concentration, 5 mM each). The medium was then subjected to centrifugation to eliminate cell debris, and the radioactivity in the supernatant was determined by scintillation spectrophotometry. Cells left attached to the plate were scraped with 0.2% Triton-X100 and also counted for radioactivity. The release of [ 3 H]AA was normalized as percentage of the total prestimulation incorporated radioactivity (the total released radioactivity plus the total cell-associated radioactivity at the end of stimulation) for the comparison of different treatment conditions.
In vitro cPLA 2 activity assay using cell lysates. Cells cultured in 75cm 2 flasks were washed four times with serum-and NaHCO 3 -free DME supplemented with 2 mg/ml BSA and 20 mM Hepes, pH 7.4, followed by incubation with the same medium for 2 h at 37 Њ C. Stimulation was started by adding the specified agonists to the cells and, after 5-10 min, stopped by rapidly aspirating away the incubating medium and replacing it with an ice-cold washing buffer containing 250 mM sucrose, 50 mM Hepes, pH 7.4, 1 mM EGTA, 1 mM EDTA, phosphatase inhibitors (200 M Na 3 VO 4 , 1 mM levamisole), and protease inhibitors (500 M PMSF, 8 M pepstatin A, 16 M leupeptin, and 1 mM diisopropyl fluorophosphate). Cells were washed four times with ice-cold washing buffer and then were scraped into an icecold assay buffer that was the same as the washing buffer except that sucrose was omitted, but the buffer was supplemented with 100 nM okadaic acid. The scraped cells were then homogenized by sonication, followed by centrifugation at 4 Њ C for 10 min at 500 g to eliminate the unbroken cells. The supernatants, defined as cell lysates, were used for cPLA 2 activity assay, using a previously described protocol with some modifications (5) . Briefly, the substrate [ 14 C]PC was dried under nitrogen, resuspended in DMSO, vigorously shaken (vortex) for 2 min, and resuspended in the assay buffer containing 10 mM CaCl 2 . The reaction was started by adding 100 l cell lysate to an equal volume of 37 Њ C substrate in an agitating water bath. The final concentrations of the components in the assay were 10 M [ 14 C]PC, 5 mM CaCl 2 , 1 mM EGTA, 1 mM EDTA, 50 mM Hepes, pH 7.4, and 10-30 g protein (measured with the Bradford assay kit; Bio-Rad Laboratories, Richmond, CA). Unless otherwise specified, 5 mg/ml BSA and 1 mM DTT were included in the final assay. After incubation for 30-40 min, the reaction was stopped by adding 750 l of 1:2 (vol:vol) chloroform/methanol. The total lipids were then extracted following the method of Bligh and Dyer (22) and subjected to TLC, as previously described (15) , using as running solvent the upper phase of the mixture of ethyl acetate/isooctane/water/acetic acid (33:45:60:6, vol/vol). The TLC plates were stained with iodine and the bands containing [ 14 C]AA that comigrated with AA standards were scraped and counted. The activity of PLA 2 was normalized as picomoles of hydrolyzed substrate/min per milligram cell lysate protein. Under these conditions, less than 3-5% of the substrates were normally hydrolyzed.
Immunoprecipitation of the 85-kD cPLA 2 . Cell lysates were prepared as described for the in vitro cPLA 2 activity assay. After the protein concentrations were matched for different samples, 400-700 g cell lysate in 0.5 ml assay buffer (the same buffer as described above for cPLA 2 activity assay) was supplemented with 1-2 l of normal rabbit serum or anti-85-kD cPLA 2 rabbit serum and 1% NP-40, followed by incubation at 4 Њ C with agitation for 1 h. The mixtures were then transferred to a microcentrifuge tube containing 24 mg protein A-Sepharose, which was precoated with 3% BSA for 2-3 h at 4 Њ C. After a 1-h incubation at 4 Њ C with agitation, the antigen-antibodyprotein A complex was precipitated by centrifugation in an Eppendorf microcentrifuge. The resultant pellets were washed three times by repeated centrifugation and resuspending in new assay buffer con-taining 1% N-P40, followed by two more washings in NP-40-free buffer. The pellets were finally resuspended either in SDS-loading buffer for SDS-PAGE and Western blotting or in the assay buffer supplemented with 5 mM DTT for the cPLA 2 activity assay.
Phosphorylation-induced mobility shift, SDS-PAGE, and Western blotting of MAP kinase. Cells cultured in a 6-well plate were washed four times with serum-and NaHCO 3 -free DME supplemented with 2 mg/ml BSA and 20 mM Hepes, pH 7.4, and incubated for 2 h at 37ЊC in the same medium, followed by stimulation with specified agonists for indicated times. The stimulation was stopped by quickly aspirating the medium and washing the cells four times with an ice-cold solution consisting of 10% glycerol, 62.5 mM Tris-HCl, pH 6.8, and protease and phosphatase inhibitors as described above. Cells were then scraped and lysed into SDS-PAGE loading buffer, followed by heating for 5 min at 100ЊC. Samples were then subjected to SDS-PAGE using either 7.5 or 10% acrylamide, with the former concentration of acrylamide requiring shorter time to run the gel and the latter requiring longer time, followed by transfer to Imobilon-P PVDF membrane. After being blocked for 1 h with 5% nonfat dry milk dissolved in PBS, the membrane carrying the proteins was sequentially incubated with 1:2,000-3,000 diluted anti-p42 MAP kinase rabbit serum for 1.5 h and with 1:2,000 diluted horseradish peroxidase-linked donkey anti-rabbit Ig for 1 h, both in 5% nonfat dry milk dissolved in PBS. Each antibody incubation was followed by washing three to four times with PBS for 5-10 min. The bands of MAP kinase in the membrane, including the mobility-shifted species due to phosphorylation, were visualized using the ECL Western blotting detection reagents following the manufacturer's instructions.
Immunoprecipitation and activity assay of MAP kinase. Immunoprecipitation and activity assay of MAP kinase were performed using a modified version of several previously published protocols (16, 23, 24) . Cells cultured in 75-cm 2 flasks were washed four times with serum-and NaHCO 3 -free DME supplemented with 2 mg/ml BSA and 20 mM Hepes, pH 7.4, followed by a 2-h incubation at 37ЊC in the same medium. Cells were then stimulated for 3 min with indicated agonists. The stimulation was stopped by quickly aspirating away the medium and washing the cells four times with ice-cold PBS supplemented with 2 mM EGTA, 1 mM EDTA, 1 mM benzamidine, 5 mM sodium pyrophosphate, and other protease and phosphatase inhibitors as specified above for cPLA 2 assay. Cells were then scraped into MAP kinase buffer consisting of 30 mM ␤-glycerophosphate, 20 mM Hepes, pH 7.4, 2 mM EGTA, 1 mM EDTA, and the protease and phosphatase inhibitors as described above for the washing solution. The scraped cells were disrupted by sonication and adjusted to the same protein concentrations for different samples before immunoprecipitation. 400 g cell lysate protein in 500 l MAP kinase buffer was supplemented with 5 l NP-40 (1% final) and 1 l anti-p42 MAP kinase serum and incubated at 4ЊC with constant agitation for 1 h. The antigen-antibody mixture thus formed was then transferred to tubes containing 24 mg protein A-Sepharose (precoated at 4ЊC with 3% BSA for 2-3 h before use) and incubated at 4ЊC with agitation for 1 h, followed by centrifugation in a microcentrifuge to precipitate the antigen-antibody-protein A complex. The pellet was sequentially washed three times with MAP kinase buffer supplemented with 1% NP-40, and three times with the same buffer without detergent. The immunoprecipitates were resuspended in 40 l MAP kinase buffer supplemented with 2 mM DTT and 4 M PKI (6-22 amide). To start the assay for MAP kinase activity, 10 l of the resuspended immunoprecipitate was added to an equal volume of substrates and MgCl 2 in MAP kinase buffer prewarmed at 30ЊC, generating (final concentrations) 10 mM MgCl 2 , 2 M PKI (6-22 amide), 40 M ATP, 2 Ci [␥-32 P]ATP and 10 g MBP. After a 20-min incubation at 30ЊC with constant agitation, the reaction was stopped by spotting 10 l of the reaction mixture to P81 phosphocellulose membrane (2 ϫ 1.5 cm), followed by washing six times for 10 min each in 125 mM phosphoric acid. The radioactivity associated with the membrane, which represented the phosphorylation of MBP by MAP kinase, was determined by scintillation spectrophotometry. Alternatively, the MAP kinase reaction was terminated by adding equal volume of twofold concentrated Laemmli's buffer and heating the mixture for 5 min, followed by SDS-PAGE and autoradiography. The major band corresponding to MBP on the exposed film was recognized, and its intensity represented MAP kinase activity.
Preparation of calcium-EGTA buffer. Desired concentration of free calcium ions in the PLA 2 assay buffer was obtained by adding appropriate amount of CaCl 2 to the buffer containing 1 mM EGTA and 1 mM EDTA, based on the calculation using the FREECA computer program (25) .
Data presentation. Unless otherwise specified, the data shown in the figures are meanϮSD of triplicate or duplicate measurements and are representative of results obtained in two to five experiments.
Results
␣ 1 -adrenergic receptors mediate AA release through the 85-kD cPLA 2 . MDCK-D1 cells are a subclone derived from parental MDCK cells, an epithelial cell line derived from distal tubule/ collecting duct of the canine kidney (26) . These cells possess a single population of ␣ 1 -adrenergic receptors, namely the ␣ 1b type, and these receptors are coupled to AA release ( Fig. 1 A and references. 21, 27, 28) . To determine whether this AA release is secondary to activation of cPLA 2 , we initially established conditions to assay the activation of this enzyme in cell lysates prepared from agonist-stimulated cells. Treatment of the cells with epinephrine increased the PLA 2 activity in the subsequently prepared cell lysates ( Fig. 1 B) . The ␣ 1 -adrenergic antagonist prazosin not only inhibited epinephrine-triggered AA release in intact cells ( Fig. 1 A) but also inhibited epinephrine-induced activation of PLA 2 activity in the cell lysates ( Fig. 1 B) . Stimulation of AA release in intact cells or activation of PLA 2 in cell lysates by the PKC activator PMA, which is cell membrane receptor independent, was not affected by prazosin. These results indicate that agonist occu- Prazosin was also included when cells were stimulated with agonists. (B) Cells were treated with prazosin and stimulated with agonists as described for panel A (except for the omission of A23187 from the PMA treatment) before cell lysates were made. Activity of PLA 2 in cell lysates was assessed as described in Methods. pancy of ␣ 1 -adrenergic receptors in MDCK-D1 cells promotes activation of a PLA 2 . No substantial release of AA in intact MDCK-D1 cells was observed during the initial period (Ͻ 10-15 min) of treatment with PMA, unless the Ca 2ϩ ionophore A23187 was also included in the medium to increase the intracellular Ca 2ϩ (data not shown), suggesting the involvement of a Ca 2ϩ -dependent PLA 2 in PMA-mediated AA release as in ␣ 1 -adrenergic receptor-promoted AA release in these cells (21) .
We hypothesized that this ␣ 1 -adrenergic receptor-coupled PLA 2 was the 85-kD cytosolic form, since the PLA 2 activity in cell lysates was insensitive to the reducing agent DTT (included in all the in vitro PLA 2 assays except for the experiment shown in Fig. 2 B) and micromolar Ca 2ϩ was sufficient for the activation of the cell lysate PLA 2 activity (see below), as expected for the 85-kD cPLA 2 . To test this hypothesis, we examined the effect of AACOCF 3 , a trifluoromethyl ketone analogue of arachidonyl acid that can inhibit the 85-kD cPLA 2 but not the 14-kD low molecular weight form of PLA 2 (29) . As shown in Fig. 2 , epinephrine-and PMA-promoted AA release were inhibited by AACOCF 3 both in intact cells (Fig. 2 A) and when assessed as PLA 2 activity in cell lysates (Fig. 2 B) . These data suggest that, in MDCK-D1 cells, ␣ 1 -adrenergic receptors, as well as PMA, induce AA release through the activation of the 85-kD cPLA 2 .
To more definitively demonstrate the coupling of ␣ 1 -adrenergic receptors to the 85-kD cPLA 2 , we examined cPLA 2 activity in immunoprecipitates obtained using anti-cPLA 2 antibody. As shown in Fig. 3 A, an 85-kD cPLA 2 (its apparent molecular weight on SDS-PAGE gel is ‫ف‬ 100 kD) could be immunoprecipitated from MDCK-D1 cell lysate with a rabbit antiserum directed against the 85-kD cPLA 2 protein, but not with the nonimmune serum, indicating the specificity of the anti-cPLA 2 antibody. We found substantial PLA 2 activity in the immuno-precipitates obtained with the anti-85-kD cPLA 2 serum, but not with the nonimmune serum, especially when assays were conducted in the presence of DTT (data not shown). DTT presumably helps to release bound cPLA 2 from the antibody by impairing the binding affinity of the antibody for its antigen as a result of the reduction of the disulfide bonds in the antibody molecule. With this experimental strategy, we found increased cPLA 2 activity in the immunoprecipitates obtained with anti-85-kD cPLA 2 serum and cell lysates derived from cells prestimulated with epinephrine or PMA (Fig. 3 B) .
Activation of the cPLA 2 by ␣ 1 -adrenergic receptors is mediated through protein phosphorylation. The stable increase in the activity of the cPLA 2 detected in cell-free systems derived from MDCK-D1 cells pretreated with agonists ( Figs. 1 B, 2 B,  and 3 B) suggested that covalent modification of the lipase was the mechanism for the change in its enzyme activity. To test whether such modification of cPLA 2 by agonists in MDCK-D1 cells was the result of phosphorylation, cell lysates were treated with potato acid phosphatase before the assay for cPLA 2 activity. This treatment abolished the increase of the cPLA 2 activity produced by incubation of cells with epinephrine or with PMA ( Fig. 4 A) . Treatment with potato acid phosphatase did not lead to proteolysis of cPLA 2 under our experimental conditions, as judged by Western blotting studies (data not shown). Thus, both ␣ 1 -adrenergic receptors and PMA ap- ]AA release in intact cells was assessed as described in Methods. Before stimulation, cells were treated with or without 150 M AACOCF 3 for 12 min. AACOCF 3 was also included with the corresponding cells during the stimulation with the indicated agonists as specified in the legend to Fig. 1 A. (B) Cells were stimulated with the agonists as indicated in the figure before cell lysates were made. PLA 2 activity in the cell lysates was assessed as described in Methods, except for the inclusion of 20 M AACOCF 3 in some assay conditions as indicated in the figure. DTT was omitted in this experiment. Figure 3 . Immunoprecipitation of the 85-kD cPLA 2 and the recovery of PLA 2 activity in the immunoprecipitates. (A) Cell lysates were immunoprecipitated either without serum (buffer only), or with nonimmune serum, or with anti-85-kD cPLA 2 serum, as described in Methods. The immunoprecipitates were resuspended in SDS loading buffer, boiled for 5 min, and subjected to SDS-PAGE. Standard 85-kD cPLA 2 was also loaded in parallel to the immunoprecipitate samples in order to define the position of this protein on the gel. The proteins were then transferred to PVDF membranes, immunoblotted with anti-85-kD cPLA 2 serum and detected by ECL as described for Western blotting of MAP kinase in Methods. (B) Cell lysates were prepared from cells stimulated with or without 100 M epinephrine or 100 nM PMA and subjected to immunoprecipitation with nonimmune serum or with anti-85-kD cPLA 2 serum as described for A. The immunoprecipitates were then assessed for PLA 2 activity as described in Methods.
pear to mediate the activation of cPLA 2 in MDCK-D1 cells through protein phosphorylation.
␣ 1 -adrenergic receptor-promoted phosphorylation and activation of MAP kinase correlates with the activation of cPLA 2 . We next sought to investigate whether ␣ 1 -adrenergic receptorpromoted phosphorylation-dependent activation of cPLA 2 occurred in MDCK-D1 cells secondary to activation of MAP kinase, as has been observed in in vitro experiments using recombinant enzyme (12, 13) . We first examined whether this receptor could cause phosphorylation and activation of MAP kinase in MDCK-D1 cells in response to the stimulation by epinephrine. Activation of MAP kinase requires tyrosine and threonine phosphorylation of the enzyme (30) . A unique feature of this activation is the molecular weight shift of the phosphorylated species of MAP kinase as assessed by SDS-PAGE, which has been used as a measure of the stimulation of MAP kinase (15, 23, 31) . We observed such a mobility shift of MAP kinase in MDCK-D1 cells in response to stimulation by a variety of agonists ( Fig. 5 A and data not shown); this mobility shift is attributable to phosphorylation because it can be reversed by treatment of the protein sample with potato acid phosphatase (data not shown). As shown in Fig. 5 A, stimulation of MDCK-D1 cells with either epinephrine or PMA caused phosphorylation of MAP kinase, as suggested by the appearance of a band with decreased molecular mobility. Epinephrine-, but not PMA-, induced phosphorylation of MAP kinase could be blocked by prazosin, suggesting that the same ␣ 1 -adrenergic receptor that is coupled to activation of cPLA 2 is also coupled to MAP kinase. In addition to the enhanced phosphorylation of MAP kinase in response to stimulation of cells by epinephrine or PMA, both agents increased MAP kinase activity (Fig. 5 B) .
To further investigate the relationship between the activation of cPLA 2 and that of MAP kinase by ␣ 1 -adrenergic receptors, we compared the time courses of the two ␣ 1 -adrenergic receptor-mediated events. As shown in Fig. 6 A, stimulation of MAP kinase by epinephrine occurred in a time-dependent manner: it became appreciable at 0.5 min, was most prominent at 3 min after treatment of cells with epinephrine, and gradually declined thereafter. Accumulation of released AA in the medium occurred somewhat more slowly but was prominent by 3 min of cell stimulation with epinephrine ( Fig. 6 B) . The stimulation of cPLA 2 activity more closely followed the stimulation of MAP kinase and was faster than AA accumulation ( Fig. 6 C) . This type of temporal relationship suggests a causeand-effect relationship between the activation of MAP kinase and that of cPLA 2 . Further support for this conclusion was obtained by the inhibition of epinephrine-promoted AA release by PD098059 ( Fig. 7) , which prevents MAP kinase activation by inhibiting MAP kinase kinase (20) . ␣ 1 -adrenergic receptor-induced activation of MAP kinase and cPLA 2 is mediated by PKC. The similar effects of epinephrine with those of PMA on the activation of cPLA 2 and MAP kinase (Figs. 1-5) suggested the possible involvement of PKC in the regulation of cPLA 2 and MAP kinase by ␣ 1 -adrenergic receptors. Previous studies from this laboratory have suggested that PKC is involved in ␣ 1 -adrenergic receptor-mediated AA release in intact MDCK-D1 cells (18, 32) . To further investigate the mechanism for this PKC involvement, we examined the effect of down-regulation of PKC on ␣ 1 -adrenergic receptor-mediated stimulation of MAP kinase and cPLA 2 . Down-regulation of PKC was achieved by incubation of cells overnight (20 h) with 200 nM PMA. Stimulation of MAP kinase by PMA and by epinephrine was completely blocked by such down-regulation of PKC ( Fig. 8 A) . Correspondingly, down-regulation of PKC completely blocked the stimulation of AA release by epinephrine and the potentiating effect of PMA on the Ca 2ϩ ionophore A23187-stimulated AA release (Fig. 8 B) . Down-regulation of PKC did not affect AA release by A23187, which has been shown to stimulate AA release in a PKC-independent manner (24) . Interpretation of the results obtained with PKC down-regulation by overnight treatment of cells with PMA, as shown in Fig. 8 , could be complicated by the fact that PKC is also involved in the desensitization of ␣ 1b receptors (33) . To circumvent this potential problem, we also tested the effect of the PKC inhibitor sphingosine on agonist stimulation of MAP kinase and AA release. As shown in Fig. 9 A, stimulation of the molecular weight shift of MAP kinase by epinephrine or PMA was blocked by sphingosine. Sphingosine treatment also blocked epinephrine-stimulated AA release ( Fig. 9 B) . In addition, sphingosine treatment or PKC downregulation blocked epinephrine-promoted activation of MAP kinase activity (Fig. 10 ). Taken together, these data demonstrate the mandatory involvement of PKC in the activation of both MAP kinase and cPLA 2 by ␣ 1 -adrenergic receptors in MDCK-D1 cells.
Alpha 1 -adrenergic receptor and protein kinase C activation increase the maximal activity of cPLA 2 . Since calcium plays a critical role in the regulation of cPLA 2 , we were interested to determine whether the ability of Ca 2ϩ to activate cPLA 2 was altered by ␣ 1 -adrenergic receptor or phorbol ester stimulation. Compared with control cells, treatment of cells with either epinephrine or PMA increased the maximal activity of PLA 2 , as assayed in subsequently prepared cell lysates (Fig. 11 ). However, we observed a similar sensitivity of the cPLA 2 to Ca 2ϩ in cells treated with or without epinephrine or PMA. Fig. 11 also illustrates that the agonist-stimulated PLA 2 activity is sensitive to Ca 2ϩ in the micromolar range, characteristic of the involvement of cPLA 2 . Taken together with the evidence presented above, these data suggest that a mechanism whereby ␣ 1 -adrenergic receptor and PMA stimulate cPLA 2 activity is to increase the maximal activity of the enzyme through phosphorylation by protein kinases in MDCK cells.
Discussion
Stimulation of AA release by ␣ 1 -adrenergic receptors has been demonstrated in a variety of cells, including FRTL5 cells (34), spinal cord neurons (35) , MDCK cells (11), vascular smooth muscle cells (36), transfected COS-1 cells (37), and striatal astrocytes (38) . Although some efforts have been made in these studies to define the molecular mechanism(s) for ␣ 1 -adrenergic regulation of AA release, no clear-cut information regarding this issue has been provided. It has been hypothesized that a PLA 2 is involved in this receptor-mediated release of AA, but definitive evidence for this hypothesis has been lacking.
The results shown here provide substantial evidence in support of the conclusion that in MDCK-D1 cells the 85-kD cPLA 2 is coupled to ␣ 1 -adrenergic receptors and is responsible for this receptor-mediated AA release. The evidence for this conclusion is several-fold: (a) The only PLA 2 that is known to be activated by membrane receptors through phosphorylation is the 85-kD form, and ␣ 1 -adrenergic receptor-stimulated activation of the PLA 2 in MDCK-D1 cells was mediated through phosphorylation ( Fig. 4) ; (b) To date, the only PLA 2 whose activation has been suggested to involve PKC is the 85-kD form, and PKC mediates the activation of the PLA 2 by ␣ 1 -adrenergic receptors in MDCK-D1 cells ( Figs. 8 and 9 ); (c) Activation of the 85-kD cPLA 2 requires micromolar Ca 2ϩ . PLA 2 activities in MDCK-D1 cell lysates are Ca 2ϩ -dependent and micromolar Ca 2ϩ provides substantial activation of the enzyme (Fig. 11) , consistent with the previous observation that omission of extracellular Ca 2ϩ blocks epinephrine-stimulated AA release in MDCK-D1 cells (21); (d) Unlike the 14-kD PLA 2 s, the ␣ 1 -adrenergic receptor-coupled PLA 2 activity is insensitive to the reducing agent DTT, which was included in the assays of PLA 2 activity in the present study (except for the experiment shown in Fig. 2 B) ; (e) The ␣ 1 -adrenergic receptor-coupled PLA 2 is sensitive to the recently characterized cPLA 2 inhibitor AACOCF 3 (Fig. 2) ; and (f ) ␣ 1 -adrenergic activation of cPLA 2 was recovered in the immunoprecipitates obtained with anti-85-kD cPLA 2 serum (Fig. 3) . AACOCF 3 has recently also been shown to inhibit a calcium-independent PLA 2 purified from P388D1 cells (39). However, calcium-independent PLA 2 is apparently not the type activated by ␣ 1 -adrenergic receptors in MDCK-D1 because receptor-promoted AA release in intact cells (21) and activation of PLA 2 activity measured in cell lysates ( Fig. 11 ) are both Ca 2ϩ dependent.
Another major effort of the present study was to define the regulatory mechanism(s) by which the 85-kD cPLA 2 is activated by ␣ 1 -adrenergic receptors in MDCK-D1 cells. In particular, we sought to define the role of PKC and MAP kinase. Based on in vitro studies of phosphorylation and activation of the recombinant 85-kD cPLA 2 by MAP kinase, it has been proposed that phosphorylation of the 85-kD cPLA 2 by MAP kinase, in coordination with an increase in the concentration of intracellular Ca 2ϩ , is the mechanism whereby membrane receptors fully activate the enzyme (12, 13) . Other evidence in favor of this mechanism is the correlation of activation of MAP kinase with that of PLA 2 activity in macrophages stimulated with zymosan particles (24) or colony-stimulating factor 1 (40) and in endothelial cells stimulated with basic fibroblast growth factor (41). In contrast, data have not previously been provided for parallel activation of endogenous MAP kinase and cPLA 2 in native cells by G protein-coupled receptors, although separate reports showing G protein receptor-coupled phosphorylation of cPLA 2 or activation of MAP kinase in different cells are available. In fact, a more complex situation regarding the role of MAP kinase in the regulation of the endogenous cPLA 2 by G protein-coupled receptors has been suggested by the findings that in Chinese hamster ovary cells or undifferentiated HL60 cells certain G protein-coupled receptors promote normal Ca 2ϩ mobilization and MAP kinase activation without inducing cPLA 2 -mediated AA release (15, 16) . These results could suggest either that a factor separate from Ca 2ϩ and MAP kinase is also required to modify the cPLA 2 molecule for its activation or that MAP kinase is not involved in the activation of the endogenous cPLA 2 by these G protein-coupled receptors. Data reported in the present study that activation of cPLA 2 temporally follows the activation of MAP kinase by ␣ 1 -adrenergic receptors ( Fig. 6 ) and that PD098059, a MAP kinase cascade inhibitor (20) , blocked ␣ 1 -adrenergic release of AA ( Fig. 7 ) strongly support the idea that MAP kinase is required for the regulation of cPLA 2 by ␣ 1 -adrenergic receptors in MDCK-D1 cells. This conclusion is further supported by the fact that blockade of MAP kinase stimulation by PKC down-regulation or by PKC inhibitor also blocks AA release ( Figs. 8-10 ).
Although MAP kinase alone (12) or both MAP kinase and PKC (13) have been reported to phosphorylate and activate recombinant cPLA 2 , most in vitro studies have shown no direct activation of cPLA 2 by PKC (12, 14) . Since MAP kinase can be activated by PKC (present study and reference 30), our data support the idea that sequential activation of PKC and MAP kinase is an important mechanism in ␣ 1 -adrenergic receptor-mediated activation of the endogenous cPLA 2 in MDCK-D1 cells. Agonist-promoted phosphorylation of cPLA 2 that involved PKC has been observed in macrophages and smooth muscle cells (42) (43) (44) although the involvement of MAP kinase in this cellular event was not addressed in these studies. The PKC-dependent activation of MAP kinase and cPLA 2 by ␣ 1 -adrenergic receptors is consistent with the kinetics of production of the native PKC activator diacylglycerol and the activation of PKC by ␣ 1 -adrenergic receptors in MDCK-D1 cells (18, 45) . Our results indicate that the effect of phosphorylation on cPLA 2 is to increase its maximal activity rather than its sensitivity to Ca 2ϩ (Fig. 11) , as also found for the activation of PLA 2 by thrombin in human platelets (46) .
In summary, we have used MDCK-D1 cells to demonstrate that the 85-kD cPLA 2 is activated by ␣ 1 -adrenergic receptors and is responsible for this receptor-promoted AA release. In addition, results in the present study strongly suggest the involvement of MAP kinase activation, secondary to the activation of PKC, in the stimulation of cPLA 2 activity by ␣ 1 -adrenergic receptors in these cells. Our present data, together with the previous work from this laboratory, lead us to propose a model whereby ␣ 1 -adrenergic receptors in MDCK-D1 cells activate the 85-kD cPLA 2 by the sequential activation of one or more forms of phospholipase C, PKC, and MAP kinase and thereby the phosphorylation of cPLA 2 . Such phosphorylation appears to increase the maximal activity of cPLA 2 rather than to change the sensitivity to intracellular Ca 2ϩ . We speculate that this may be a general mechanism whereby G proteinlinked receptors stimulate AA release and formation of products of AA metabolism. Cell lysates were then prepared and immunoprecipitated for MAP kinase as described in Methods. The immunoprecipitated MAP kinase was assayed for kinase activity using MBP and [␥-32 P]ATP as substrates. The kinase assay reaction was terminated by adding equal volume of twofold concentrated Laemmli's buffer and heating for 5 min, followed by SDS-PAGE. After drying, the gel was exposed to film, and the major band corresponding to MBP was recognized as shown in the figure. Figure 11 . Calcium concentration-response of cPLA 2 activity from MDCK-D1 cells treated with epinephrine or PMA. Cells were incubated with vehicle (Control) or 100 M epinephrine or 100 nM PMA, followed by preparation of cell lysates. PLA 2 activity in the cell lysates was assessed in the presence of increasing concentrations of free Ca 2ϩ prepared as described in Methods. Each point in the figure represents the meanϮSEM of data obtained from four independent experiments except for the point of 10 Ϫ4 M which is the average of three experiments.
